Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors

Craig, D.G.N.; Thimappa, R.; Anand, V.; Sebastian, S.
May 2010
QJM: An International Journal of Medicine;May2010, Vol. 103 Issue 5, p327
Academic Journal
Background: Intravenous (IV) proton pump inhibitors (PPI) reduce rebleeding from high-risk peptic ulcers following endoscopic therapy. The majority of IV PPI prescriptions in US hospital practice are inappropriate, leading to unnecessary drug costs, drug shortages and potential adverse events. To date, little is known about UK hospital IV PPI prescribing practice.


Related Articles

  • Use of acid-suppression therapy for treatment of non-variceal upper gastrointestinal bleeding. Olsen, Keith M. // American Journal of Health-System Pharmacy;5/15/2005 Supplement 2, Vol. 62, pS18 

    Purpose. Prognostic factors in patients with peptic ulcer bleeding and therapeutic strategies for preventing the recurrence of bleeding are described. Summary. The risk of complications and death in a patient with acute upper gastrointestinal bleeding can be predicted based on certain clinical...

  • How Do PPIs Affect Patients with Bleeding Ulcers? Shaughnessy, Allen F. // American Family Physician;8/15/2005, Vol. 72 Issue 4, p683 

    Presents the results of a case study regarding the effectiveness of proton pump inhibitor (PPI) on patients with bleeding peptic ulcers. Factor which enhances platelet function and inhibit fibrolysis in patients with an acute bleeding peptic ulcer; Effect of PPI treatment on mortality rates...

  • Test for GERD Reveals That Many Are Taking Medications Unnecessarily.  // Women's Health Advisor;Sep2013, Vol. 17 Issue 9, p5 

    The article focuses on the increased inappropriate use of proton pump inhibitors (PPI) by people without being diagnosed with gastro esophageal reflux disease (GERD). It suggests for early diagnosis of GERD by esophageal power of hydrogen (Ph) monitoring following an endoscopy which helps to...

  • Continuous Infusion of Pantoprazole versus Ranitidine for Prevention of Ulcer Rebleeding: A U.S. Multicenter Randomized, Double-Blind Study. Jensen, Dennis M.; Pace, Samuel C.; Soffer, Elaine; Comer, Gail M. // American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p1991 

    OBJECTIVES: No North American randomized study has compared ulcer rebleeding rates after endoscopic hemostasis in high-risk patients treated with high-dose intravenous (IV) proton pump inhibitors (PPIs) or IV histamine-2 receptor antagonists. Our hypothesis was that ulcer rebleeding with IV...

  • Proton Pump Inhibitors After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding. Mesihovic, Rusmir; Vanis, Nenad; Mehmedovic, Amila; Gornjakovic, Srdjan; Gribajcevic, Mehmed // Medicinski Arhiv;2009, Vol. 63 Issue 6, p323 

    Background: Peptic ulcer bleeding is a common and potentially fatal condition. For patients with bleeding peptic ulcers that display major endoscopic stigmata of recent hemorrhage, a combination of endoscopic and pharmacologic therapy is the current standard management. Objective: To show our...

  • Esophagitis in a High H. pylori Prevalence Area: Severe Disease Is Rare but Concomitant Peptic Ulcer Is Frequent. Ponce, Julio; Calvet, Xavier; Gallach, Marta; Ponce, Marta // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Few data are available on the prevalence of erosive and severe esophagitis in Western countries. Objective: To retrospectively determine the prevalence and the factors predicting erosive esophagitis and severe esophagitis in a large series of endoscopies in Spain. Design:...

  • Proton pump inhibitors for acid suppression in the intensive care unit: Formulary considerations. Devlin, John W. // American Journal of Health-System Pharmacy;5/15/2005 Supplement 2, Vol. 62, pS24 

    Purpose. The rationale for limiting the proton pump inhibitor (PPI) products included in an institutional formulary, factors to consider when making formulary decisions about PPI products, the results and limitations of cost-effectiveness analyses of PPI therapy in critically ill patients, the...

  • Proton pump inhibitors (PPIs)--too much of a good thing? Bryant, Linda // Journal of Primary Health Care;Mar2012, Vol. 4 Issue 1, p72 

    The article offers information on proton pump inhibitors (PPIs). Prescribed classes of medicines under the PPI category include omeprazole, pantoprazole and lansoprazole. Their indication include gastro-oesophageal reflux disease (GORD) and peptic ulcer disease. Common, less common and rare side...

  • Effect of rebamipide on quality of peptic ulcer healing in rat. Zhu Qi; Li Jie; Cao Haixia; Zhao Xiaoying; Qi, Zhu; Jie, Li; Haixia, Cao; Xiaoying, Zhao // Digestive Diseases & Sciences;Sep2009, Vol. 54 Issue 9, p1876 

    The aim of this study is to elucidate the effects and the mechanism of rebamipide, omeprazole, and their combination treatment on quality of peptic ulcer healing (QOUH). Peptic ulcer models were induced by acetic acid exposure of the serosa of rat stomach. Forty Sprague-Dawley (SD) rats were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics